BNT324

DRUG4 trials

Sponsors

BioNTech SE, Dualitybio Inc.

Conditions

Advanced Lung CancerCervical cancer (CC)Hepatocellular carcinoma (HCC)MelanomaMetastatic Castration-resistant Prostate CancerNon-small cell lung cancer (NSCLC)Ovarian cancer (OC)Squamous cell carcinoma of head and neck

Phase 1

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

RecruitingNCT06892548

BioNTech SEAdvanced Lung Cancer

Start: 2025-05-02End: 2031-06-01Target: 594Updated: 2026-05-19

A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer

Not yet recruitingCTIS2024-520238-31-01

BioNTech SEAdvanced Lung Cancer

Target: 26Updated: 2026-02-24

Phase 2

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Not yet recruitingCTIS2025-523895-22-00

Dualitybio Inc.Cervical cancer (CC), Hepatocellular carcinoma (HCC), Melanoma +3

Target: 57Updated: 2026-05-13

Phase 3

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

RecruitingNCT07365995

BioNTech SEMetastatic Castration-resistant Prostate Cancer

Start: 2026-04-22End: 2031-02-01Target: 736Updated: 2026-05-05